Morgan Stanley analyst Michael Ulz maintained a Hold rating on Sarepta Therapeutics today and set a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz’s rating is based on a combination of factors, primarily revolving around the ongoing regulatory scrutiny and safety concerns associated with Sarepta Therapeutics’ Elevidys. The recent negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the conditional marketing authorization in the European Union has added to these concerns. Additionally, the FDA’s investigation into the death of a patient who received Elevidys, although deemed unrelated to the therapy, has further contributed to the cautious stance.
Given these uncertainties, Michael Ulz maintains a Hold rating, reflecting a wait-and-see approach as the situation develops. The company and its partner, Roche, are actively engaging with regulatory bodies to address these issues and explore potential paths forward. However, until there is more clarity on the safety and regulatory status of Elevidys, the recommendation remains cautious.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $12.00 price target.